Semaglutide：|GLP-1| and lossing weight CAS 910463-68-2

Desciption

Semaglutide:GLP-1
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes

Why Choose ?
With its unique dual-action formula, Semaglutide is offering a comprehensive approach to your health.

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating.

One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose).

Mimics the GLP-1 hormone released in the gut
Semaglutide and similar drugs, such as dulaglutide and liraglutide, have been used to treat binge eating disorder (BED), as they can successfully minimize obsessive thoughts about food and binging urges.^[30]^[31] Some users of these drugs have reported significant reduction in what is colloquially known as "food noise" (constant, unstoppable thoughts about eating despite not being physically hungry), which can be a factor of BED

Join the Revolution in Health

Embrace the change with Semaglutide and start your journey towards a healthier, more vibrant life today. Discover the difference and transform your health with Semaglutide.

Product picture:

Understanding Semaglutide

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating.

One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). For that reason, health care providers have used semaglutide for more than 15 years to treat Type 2 diabetes.

But GLP-1 in higher amounts also interacts with the parts of the brain that suppress your appetite and signal you to feel full. When used in conjunction with diet and exercise, it can cause significant weight loss — and a reduced risk of cancer,diabetes and heart disease — in people who are obese or overweight.

Specifications

Aliase	Semaglutide
CAS	910463-68-2
MOLECULAR FORMULA	C187H291N45O59
MOLECULAR WEIGHT	4113.57754

Our Service Advantages

Packaging and Delivery
The company fully supports customized packing and shipping preferences to meet specific needs, ensuring top priority for customer requirements.

Supply Ability
The MOQ varies by product due to their unique specifications. We encourage you to reach out for detailed information tailored to the specific product of interest.

Lead Time
Delivery schedules adapt to seasonal demands, with a 15 working day delivery time during peak seasons and 7 to 13 working days in off-peak seasons, showcasing efficient and timely delivery.

Semaglutide injections for weight loss

Semaglutide Research
In June 2008, a phase II clinical trial began studying semaglutide.

In 2012, a team of researchers at Novo Nordisk developed semaglutide for a once-weekly diabetes therapy as a longer-acting alternative to liraglutide. It was given the brand name Ozempic. Clinical trials started in January 2016 and ended in May 2017.

In March 2021, in a phase III randomized, double-blind, trial, 1,961 adults with a body mass index of 30 or greater were assigned in a 2:1 ratio to a treatment with once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. The trials occurred at 129 sites in 16 countries in Asia, Europe, North America, and South America. The mean percentage change in body weight at week 68 was −14.9% in the semaglutide group vs −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points (95% CI, −13.4 to −11.5).

A 2022 review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery.

In March 2023, a Novo Nordisk official said that patients using semaglutide to lose weight can regain their original weight within 5 years of stopping treatment.

FAQ

1.Manufacturer or trading company? Where is the company located?
We pride ourselves on being an integrated industry and trade company, nestled in the heart of Zhengzhou, Henan Province.

2.Where are the main markets?
Our global footprint extends across Europe, America, Southeast Asia, the Middle East, and Africa. We are committed to delivering high-quality products and services to every corner of the world, ensuring our presence is felt internationally.

3.Can you provide a product catalog?
Yes, we can! Please contact our sales manager directly. We will promptly send you our detailed product catalog and pricing information to suit your needs.

4.About the terms and conditions of payment.
We offer a variety of payment options to accommodate your convenience, including T/T (Telegraphic Transfer), Western Union, MoneyGram, and cryptocurrency options, ensuring a seamless transaction process.

About US
Nestled in the heart of Henan Province, Zhengzhou Plastic Body Peptide Trading Co., Ltd embarked on its journey to redefine the chemical and pharmaceutical landscape. Founded on the principles of innovation, integrity, and excellence, we've dedicated ourselves to producing top-tier local anesthetics, pharmaceutical intermediates, steroids, and other crucial raw materials.

Driven by a passion for progress and a commitment to quality, our team has bridged continents, connecting with partners in North America, Eastern Europe, Southeast Asia, and beyond. Each product and solution we develop carries the mark of our rigorous research and customer-centric approach, aiming not just to meet but exceed global standards.

References

1.Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today’s Diabetes Therapy. Front Endocrinol (Lausanne). 2019 Apr 26;10:260. doi: 10.3389/fendo.2019.00260. PMID: 31080438; PMCID: PMC6497767.

2.Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006. PMID: 17928588.

3.Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, Kimble SD, Nadler JL. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun. 2006 Jun 9;344(3):1017-22. doi: 10.1016/j.bbrc.2006.03.177. Epub 2006 Apr 5. PMID: 16643856.

4.Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 2000 Jul;6(7):802-7. doi: 10.1038/77535. PMID: 10888930.

5.van Bloemendaal, L., IJzerman, R. G., Ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014). GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes, 63(12), 4186–4196. https://doi.org/10.2337/db14-0849

6.Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021). Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in therapy, 38(6), 2821–2839. https://doi.org/10.1007/s12325-021-01710-0